Welcome to our dedicated page for Icu Medical SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICU Medical SEC filings document the company’s medical-device operations, public-company governance and recurring financial disclosures. Form 8-K reports furnish quarterly earnings releases, including GAAP results, non-GAAP reconciliations, adjusted EBITDA, adjusted diluted earnings per share, product-line revenue and the reporting effects of the completed IV Solutions divestiture.
Proxy materials describe annual meeting matters, board and compensation governance, executive compensation and equity-award disclosures. Other current reports cover officer and compensation arrangements, including amendments to the ICU Medical Executive Severance Plan. Together, the filings record the company’s capital-market reporting obligations, governance practices and operating results for its infusion systems, consumables and critical care product categories.
Form 144 notice reporting proposed sales of common-equity awards. The excerpt lists proposed disposals tied to equity compensation: 569 Performance Stock Units dated 02/15/2019, 282 Performance Stock Units dated 01/17/2020, and 1,272 restricted shares vesting under a registered plan dated 02/13/2020. The filing shows an administrative header with a dollar figure $280,684.80 and an entry 2,123 (context not fully detailed) dated 05/22/2026.
ICU Medical Inc. President Daniel Woolson reported an open-market sale of 2,123 shares of Common Stock. The shares were sold at a weighted average price of $132.2114 per share, with individual trade prices ranging from $132.03 to $132.33. After this transaction, Woolson directly holds 22,479 shares of ICU Medical common stock. The filing notes that detailed trade-by-trade pricing information is available upon request.
ICU Medical, Inc. reported results from its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Amended and Restated Certificate of Incorporation to replace certain supermajority requirements with simple majority voting and to grant stockholders owning at least 25% of voting power the right to call special meetings.
These Charter Amendments became effective when the amended charter was filed in Delaware, and the Board implemented conforming changes through Amended and Restated Bylaws, including detailed procedures and informational requirements for special meeting requests. All director nominees were elected, Deloitte & Touche LLP was ratified as auditor for the year ending December 31, 2026, and executive compensation was approved on an advisory basis.
Stockholders also approved an adjournment authority related to Proposal 5 if needed. An advisory stockholder proposal to establish a 10% stockholder special meeting right did not pass, leaving the new 25% ownership threshold as the governing standard for stockholder-called special meetings.
ICU Medical Inc. executive reports stock sale. VP and General Counsel Virginia Ruth Sanzone sold 2,447 shares of ICU Medical common stock in an open-market sale at $124.08 per share. After this transaction, she directly holds 19,460 shares, so the sale represents a modest portion of her overall position.
Morgan Stanley Smith Barney LLC submitted a Form 144 disclosing proposed resale of Common shares of ICUI tied to Performance Stock Units. The notice lists PSU grant dates 03/06/2023 (344 shares), 03/08/2023 (1,076 shares) and 03/08/2024 (1,027 shares). The filing references NASDAQ and a transaction date of 05/14/2026. The filing is a routine resale notice of shares associated with issuer awards.
ICU Medical director Kolleen T. Kennedy reported compensation-related equity activity in the company’s stock. On May 13, 2026, 1,254 Restricted Stock Units vested and were settled into an equal number of ICU Medical common shares, bringing her direct holdings to 4,539 shares.
On the same date, Kennedy also received a new grant of 1,475 Restricted Stock Units. According to the disclosure, these units have no purchase or exercise price and will vest on the anniversary of the grant date or at the following annual stockholder meeting, whichever occurs first.
ICU Medical director Laurie Hernandez reported routine equity compensation activity. On May 13, 2026, she exercised 1,254 Restricted Stock Units into Common Stock, bringing her direct holdings to 4,862 shares.
On the same date, she received a new grant of 1,475 Restricted Stock Units, which vest on the anniversary of the grant or the following stockholder meeting, whichever occurs first. The Restricted Stock Units have no purchase or exercise price.
ICU Medical director Elisha W. Finney reported equity compensation activity involving Restricted Stock Units (RSUs). On May 13, 2026, 1,254 RSUs were exercised into the same number of shares of common stock, increasing direct share ownership to 5,249 shares after the transaction. The filing also shows a new award of 1,475 RSUs, which carry no purchase or exercise price and are scheduled to vest on the first anniversary of the grant date or at the next annual stockholder meeting, whichever occurs first. These transactions reflect routine director compensation rather than open-market buying or selling.
ICU Medical director Donald Abbey reported compensation-related equity activity, not open-market trading. On May 13, 2026, Abbey exercised derivative securities to acquire 1,254 shares of Common Stock and received a new grant of 1,475 Restricted Stock Units, which have no purchase or exercise price and vest on the earlier of the grant anniversary or the next annual stockholder meeting. Following these transactions, Abbey directly holds 6,004 shares of Common Stock and 1,475 Restricted Stock Units tied to Common Stock.
ICU Medical director David F. Hoffmeister reported compensation-related equity activity. On May 13, 2026, he acquired 1,254 shares of Common Stock through the exercise of previously granted Restricted Stock Units, bringing his direct holdings to 6,004 shares of Common Stock.
On the same date, he also received a new award of 1,475 Restricted Stock Units. These RSUs have no purchase or exercise price and are scheduled to vest on the anniversary of the grant date or at the following annual stockholder meeting, whichever occurs first. The filing shows no open-market purchases or sales.